STUDY
STUDY DESIGN
TOTAL NO OF PATIENTS
MALE (%)
MALE (%)
Age Mean (±SD) Age Mean (±SD)
BMI (kg/m2) Mean (±SD)
BMI (kg/m2) Mean (±SD)
ASA Score 1/2/3/4 ASA Score 1/2/3/4
OPERATION TIME, MEAN SD
OPERATION TIME, MEAN SD
CIPROFOL PROPOFOL CIPROFOL PROPOFOL CIPROFOL PROPOFOL CIPROFOL PROPOFOL CIPROFOL PROPOFOL
Zeng Y 2022 multicenter, randomized, open-label, propofol-controlled phase 2 clinical trial 40 11 (36.7) 3 (30.0) 42.5 ± 10.3 46.4 ± 11.2 23.7 ± 3.0 23.6 ± 3.6 16/14/0/0 4/6/0/0 105.3 ± 62.6
Wang X 2022 phase 3, multicenter, randomized, double-blind, comparative study 176 32 31 38.5 (12.1) 41.1 (11.1) 23.3 (2.9) 23.3 (3.1) 51/37/0/0 48/40/0/0 -
Qin K 2022 prospective, randomized, single-blind study 105 18 (34.6) 18 (34.0) 39.00±10.10 41.25±10.63 23.38±3.33 22.63±2.38 0/0/42/10 0/0/44/9 175.88±42.22
Chen-Ben Zhen 2022 prospective, double-blind, single-center study 120 - - 33.9±9.1 33.8±9.6 22.2±3.2 21.4±2.8 32/28/0/0 34/26/0/0 55.2±20.5
Liang Peng 2023 multicenter, single-blinded, propofol-controlled, randomized, phase 3 trial 128 23 (26.7) 10 (23.8) 38.5 ± 10.1 40.5 ± 10.1 23.3 ± 2.8 23.3 ± 3.0 48/38/0/0 22/20/0/0 94.6 ± 39.2
Zhu Qianmei 2023
phase 2a, 7-center, open-labeled, non-randomized and positive controlled clinical trial
68
0.4mg 0.5mg 4 13
16
53.5 ± 8.3 46.6 ± 12.4
44.8 ± 12.4
24.4 ± 2.5 23.8 ± 2.6
24.4 ± 3.0
6/2/0/0 7/22/0/0
14/17/0/0
102.6 ± 44.4 81.8 ± 47.9
Man Yan 2023 randomized double-blind controlled study 128 - - 42.2±9.46 44.1±9.4 22.8±2.2 23.3±2.6 18/46/0/0 14/50/0/0 -